Klinikum der Universität zu Köln

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials
• Neuroendocrine tumours1 trial
• Prostate cancer1 trial

Phase

• Phase 1/21 trial
• Phase 21 trial
• Phase 31 trial

Status

• Active, not recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Revolution Medicines, Inc.1 trial
• SpectraCure AB (publ)1 trial
• Technische Universität Dresden1 trial

Running trials

• Not yet recruiting

  Open-label clinical phase 1/2 study to assess the safety and efficacy of the SpectraCure P18 System and verteporfin for injection for the treatment of primary localized prostate cancer

  2024-519658-35-00· Phase 1/2· SpectraCure AB (publ)· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· Phase 3· Revolution Medicines, Inc.· Source

• Active, not recruiting

  A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

  NCT05470595· Phase 2· Technische Universität Dresden· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer1 recruiting